Please use this identifier to cite or link to this item: http://hdl.handle.net/1843/56342
Full metadata record
DC FieldValueLanguage
dc.creatorNayara Felicidade Tomazbrazpt_BR
dc.creatorNatalia Pessoa Rochapt_BR
dc.creatorÉrica Leandro Marciano Vieirapt_BR
dc.creatorRodrigo Santiago Gomezpt_BR
dc.creatorIzabela Guimarães Barbosapt_BR
dc.creatorOlívio Brito Malheiropt_BR
dc.creatorAdriana Maria Kakehasipt_BR
dc.creatorAntonio Lucio Teixeirapt_BR
dc.date.accessioned2023-07-14T23:08:23Z-
dc.date.available2023-07-14T23:08:23Z-
dc.date.issued2017-05-09-
dc.citation.volume38pt_BR
dc.citation.spage1405pt_BR
dc.citation.epage1413pt_BR
dc.identifier.doi10.1007/s10072-017-2964-zpt_BR
dc.identifier.issn15901874pt_BR
dc.identifier.urihttp://hdl.handle.net/1843/56342-
dc.description.resumoAbstract This current study aimed to evaluate the frequency of low bone mass, osteopenia, and osteoporosis in patients with myasthenia gravis (MG) and to investigate the possible association between bone mineral density (BMD) and plasma levels of bone metabolism markers. Eighty patients with MG and 62 controls BMD were measured in the right femoral neck and lumbar spine by dual-energy X-ray absorptiometry. Plasma concentrations of osteocalcin, osteopontin, osteopro tegerin, tumor necrosis factor (TNF-α), interleukin (IL)-1β, IL-6, dickkopf (DKK-1), sclerostin, insulin, leptin, adrenocorticotropic hormone, parathyroid hormone, and fibroblast growth factor (FGF-23) were analyzed by Luminex®. The mean age of patients was 41.9 years, with 13.5 years of length of illness, and a mean cumulative dose of glucocorticoids 38,123 mg. Patients had significant reduction in BMD of the lumbar, the femoral neck, and in the whole body when compared with controls. Fourteen percent MG patients had osteoporosis at the lumbar spine and 2.5% at the femoral neck. In comparison with controls, patients with MG presented lower levels of osteocalcin, adrenocorticotropic hormone, parathyroid hormone, sclerostin, TNF-α, and DKK-1 and higher levels of FGF-23, leptin, and IL-6. There was a significant negative correlation between cumulative glucocorticoid dose and serum calcium, lumbar spine T-score, femoral neck BMD,T-score, and Z-score. After multivariate analysis, higher TNF-α levels increased the likelihood of presenting low bone mass by 2.62. MG patients under corticotherapy presented low BMD and altered levels of bone markers.pt_BR
dc.format.mimetypepdfpt_BR
dc.languageengpt_BR
dc.publisherUniversidade Federal de Minas Geraispt_BR
dc.publisher.countryBrasilpt_BR
dc.publisher.departmentMED - DEPARTAMENTO DE APARELHO LOCOMOTORpt_BR
dc.publisher.departmentMED - DEPARTAMENTO DE CLÍNICA MÉDICApt_BR
dc.publisher.departmentMED - DEPARTAMENTO DE SAÚDE MENTALpt_BR
dc.publisher.initialsUFMGpt_BR
dc.relation.ispartofNeurological Sciences-
dc.rightsAcesso Restritopt_BR
dc.subjectMyasthenia gravispt_BR
dc.subjectBone mineral densitypt_BR
dc.subjectBone metabolism markerspt_BR
dc.subjectOsteoporosispt_BR
dc.subjectDual-energy X-ray absorptiometrypt_BR
dc.subject.otherMiastenia Gravispt_BR
dc.subject.otherDensidade Ósseapt_BR
dc.subject.otherOsteporosept_BR
dc.subject.otherAbsorciometria de Fótonpt_BR
dc.titleNegative impact of high cumulative glucocorticoid dose on bone metabolism of patients with myasthenia gravispt_BR
dc.typeArtigo de Periódicopt_BR
dc.url.externahttps://link.springer.com/article/10.1007/s10072-017-2964-z-
Appears in Collections:Artigo de Periódico

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.